Nihon Decoluxe Co., Ltd. (XNGO:7950)

Elevation Oncology Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	-	626	719	814	415	452
Depreciation & Amortization	-	274	377	324	331	355
Loss (Gain) From Sale of Investments	-	-	-	-306	-2	-
Other Operating Activities	-	-183	-348	-28	-148	-128
Change in Accounts Receivable	-	111	-43	-423	57	176
Change in Inventory	-	85	-	-339	-115	110
Change in Accounts Payable	-	-25	12	187	198	-249
Change in Other Net Operating Assets	-	-129	104	57	-71	-89
Operating Cash Flow	-	759	821	286	665	627
Operating Cash Flow Growth	-	-7.55%	187.06%	-56.99%	6.06%	-40.96%
Capital Expenditures	-	-154	-275	-225	-32	-83
Sale (Purchase) of Intangibles	-	-1	-19	-18	-25	-1
Investment in Securities	-	-1,992	-474	1,303	214	-496
Other Investing Activities	-	-2	-2	-1	31	-1
Investing Cash Flow	-	-2,149	-770	1,059	188	-581
Repurchase of Common Stock	-	-99	-	-	-111	-
Dividends Paid	-	-293	-316	-207	-210	-194
Other Financing Activities	-	-	-	-	-1	-
Financing Cash Flow	-	-392	-316	-207	-322	-194
Foreign Exchange Rate Adjustments	-	-17	-	18	35	-
Miscellaneous Cash Flow Adjustments	-	-	-1	-	-	-1
Net Cash Flow	-	-1,799	-266	1,156	566	-149
Free Cash Flow	-	605	546	61	633	544
Free Cash Flow Growth	-	10.81%	795.08%	-90.36%	16.36%	-43.97%
Free Cash Flow Margin	-	9.74%	8.70%	1.08%	12.90%	11.56%
Free Cash Flow Per Share	-	765.38	689.02	76.97	786.70	669.78
Cash Income Tax Paid	-	183	344	32	156	137
Levered Free Cash Flow	-	519.5	364.25	97.88	481.13	529.38
Unlevered Free Cash Flow	-	519.5	364.25	97.88	481.13	529.38

Updated Jan 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.